To investigate the epidemiology, treatment outcomes, and survival of cervical cancer in Kazakhstan over a 10-year period (2014–2023) prior to the implementation of a national HPV vaccination program.
Key Findings:
Cervical cancer prevalence increased gradually over the 10-year period.
Age-standardized incidence rate (ASIR) peaked at 17.22 per 100,000 women in 2022.
Age-standardized mortality rate (ASMR) peaked at 6.92 per 100,000 women in 2022.
Disability-adjusted life year (DALY) rates increased to 255.24 per 100,000 women in 2022.
5-year survival rate was 65.3%, with poor outcomes in advanced stages.
Interpretation:
Remove this section as it contains unsupported claims.
Limitations:
Data may not fully capture all cervical cancer cases due to potential underreporting.
The study does not account for the impact of the newly launched HPV vaccination program.
Conclusion:
Revise to focus solely on the findings without implications for future comparisons.
